Search Results for: GENE CELL THERAPY Its Growing
Articles
TTP introduces Cellular Origins, Focused on Delivering Ccalable Manufacture of Cell & Gene Therapies January 17, 2023
TTP plc recently announced the launch of Cellular Origins, a TTP Company. Cellular Origins is a TTP spin-out, created to...Transgene Receives Approval to Start a Phase 1 Trial of Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration January 6, 2023
Transgene recently announced it has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a Phase 1 clinical trial of TG6050, a novel oncolytic….
Gerresheimer to Expand Significantly in High Value Solutions & Further Accelerates its Sustainable Profitable Growth December 6, 2022
Gerresheimer AG recently reaffirmed its growth agenda and increased its revenue and adjusted EBITDA guidance. The company continues to execute...Taconic Biosciences Launches First & Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors for Improved Antibody Therapy Assessment October 24, 2022
Taconic Biosciences has recently launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine...Catalent Expands Biologics Analytical Capabilities With New Laboratories at Center of Excellence in Kansas City, MO October 20, 2022
Catalent recently announced a $12-million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City,...EXTRACELLULAR VESICLES - Engineering Extracellular Vesicles to Create Next-Generation Therapeutics October 3, 2022
David Lowe, PhD, Justin Hean, PhD, Dave Carter, PhD, and Antonin de Fougerolles, PhD, say EVs exhibit key properties that make them extremely attractive as therapeutics, particularly their safety profile and potential for low immunogenicity. In order to effectively unlock this potential, some key challenges remain, such as the development of EV product manufacture and characterization methodologies and rapid pharmacokinetics.
ProtaGene Names Pharmaceutical Industry Leader Raymond Kaiser as CEO to Drive Next Stages of Growth September 20, 2022
ProtaGene GmbH recently announced the appointment of Raymond Kaiser, PhD, as Chief Executive Officer. Ray will drive the continued innovation….
SiSaf Announces Positive Preclinical Data for its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis September 12, 2022
SiSaf Ltd, an RNA delivery and therapeutics company, recently announce positive data confirming safety and efficacy of its Bio-Courier next-generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an….
Immatics Announces First Cancer Patient Treated With Second-Generation ACTengine TCR-T Candidate August 23, 2022
Immatics N.V. recently announced the treatment of the first patient in its Phase 1b expansion cohort C (NCT03686124) evaluating IMA203CD8,...N4 Pharma Highlights Potential of Nuvec as Gene Therapy Delivery Platform May 20, 2022
A recent preclinical in-vivo study found that Nuvec – N4 Pharma’s novel silica-based nanoparticle – formulated with TNF-α pDNA oncotherapy, suppressed tumor growth and improved survival of….
Catalent Acquires Commercial-Scale Cell Therapy Development & Manufacturing Facility From Erytech April 25, 2022
Catalent recently announced it has acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, NJ, for...CELL & GENE THERAPY - State of the Industry – Where is C> Headed? April 5, 2022
Bill Vincent believes if the industry wants to keep moving up the steep growth curve, then capacity and raw materials must be readily available. The innovations in therapies, platforms, and processes will all come with time, money, and increasing availability of resources.
EXECUTIVE INTERVIEW - Syner-G BioPharma: A Track Record of CMC Excellence April 4, 2022
Prabu Nambiar, PhD, Founder and CEO Syner-G, discusses the company’s evolution, its approach to CMC, and the future of the organization.
BioNTech & Regeneron Expand Strategic Collaboration March 8, 2022
BioNTech SE recently announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor….
GENE EDITING TECHNOLOGY - Harnessing a Cell’s Natural DNA Repair Process to Develop Medicines With Higher Levels of Precision & Durability March 1, 2022
Mariana Nacht, PhD, reviews a new gene editing approach that harnesses a cell’s natural DNA repair process, known as homologous recombination, to insert a corrective copy of the gene (or transgene) at a precise spot in a patient’s genome.
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III & Stage IV Non-Small Cell Lung Cancer January 18, 2022
EQRx, Inc. recently announced data from its partner CStone Pharmaceuticals’ two pivotal Phase 3 studies of the anti-PD-L1 monoclonal antibody...EXOSOMES - The Next Evolution in Therapy Delivery Beyond the Cell Membrane: The Promise of Exosomes January 17, 2022
Linda Marbán, PhD, says perhaps the best way to get past the cell membrane is to deliver contents the same way that cells send information to each other. And that is by the exosome, which in the case of targeted therapy delivery, has been identified as an alternative that shows powerful promise.
PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy January 10, 2022
PDS Biotechnology Corporation recently announced it has been granted US Patent Application No. 15,724,818 titled Novel HPV16 Non HLA-Restricted T-cell...Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline December 13, 2021
Precision BioSciences, Inc. recently announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD) presented at….
BrainStorm Cell Therapeutics & Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing December 7, 2021
BrainStorm Cell Therapeutics Inc. and Catalent recently announced that the technology transfer for NurOwn manufacturing at Catalent’s facility has been finalized….
